

MBS Review Taskforce - Pathology Endocrine Tests

Thank you for your interest in participating in the MBS Review public consultation for the Pathology Clinical Committee - Endocrine Tests report.

This public consultation allows the Australian public, including health professionals, an opportunity to provide feedback on the Pathology Clinical Committee - Endocrine Tests draft report, prior to the final recommendations being provided to government. You can review the [full draft report](#) or the [Summary for consumers](#).

The online consultation survey includes the following sections:

- Responses to the 16 recommendations in the Pathology Clinical Committee - Endocrine Tests draft report (including links to each report recommendation and a summary for consumers to allow for easy reflection on the recommendations)
- 3 questions to provide feedback on the draft report
- 3-4 demographic questions
- 2 questions on privacy and consent of responses.

You can also review a [PDF of the survey questions](#).

Please note: only submissions submitted through this online survey process will be considered.

As part of the first section, you will be given an opportunity to upload additional documents relevant to your feedback or supporting evidence to your response.

You are able to save your responses and return to the survey using the 'Save and Continue Later' button. You can also review and print your responses prior to submitting your completed survey.

This survey will close at 5pm (AEDT) Wednesday 4 October 2017.

By clicking the 'Next' button, you are consenting to participate in the MBS Review Public Consultation for the Pathology Clinical Committee - Endocrine Tests report.

Feedback on Recommendations

Recommendation 1 - TSH (thyroid-stimulating hormone)

Do you agree with Recommendation 1 which proposes to provide clearer guidance on when the test for item 66716 is appropriate for doctors to request?

Refer to [Section 5.1.1](#) and the [Summary for consumers](#).

Yes

No

Yes, with some changes

Don't know / Prefer not to say

[If 'No' or 'Yes, with some changes' Max word count = 500]

Please provide suggested changes, including your reasoning or evidence

Recommendation 2 - TFTs (thyroid function tests)

Do you agree with Recommendation 2 which proposes to provide clearer guidance on when the test for item 66719 is appropriate for doctors and pathologists to allow the pathologist to determine when 66719 is necessary based on the initial TSH test?

Refer to [Section 5.1.2](#) and the [Summary for consumers](#).

- Yes
- No
- Yes, with some changes
- Don't know / Prefer not to say

[If 'No' or 'Yes, with some changes' Max word count = 500]

Please provide suggested changes, including your reasoning or evidence

Recommendation 3 – New item for TFTs (thyroid function tests)

Do you agree with Recommendation 3 which proposes to create a new MBS item that includes the measurement of all thyroid hormone levels in patients with totally suppressed thyroid-stimulating hormone (TSH)?

Refer to [Section 5.1.3](#) and the [Summary for consumers](#).

- Yes
- No
- Yes, with some changes
- Don't know / Prefer not to say

[If 'No' or 'Yes, with some changes' Max word count = 500]

Please provide suggested changes, including your reasoning or evidence

Recommendation 4 – Oral glucose tolerance and challenge tests

Do you agree with Recommendation 4 which proposes to remove item 66545 (Oral glucose challenge test) from the MBS and consolidate item 66542 under 66548 and include use in pregnant women and certain specific patient groups?

Refer to [Section 5.2.1](#) and the [Summary for consumers](#).

- Yes
- No
- Yes, with some changes
- Don't know / Prefer not to say

[If 'No' or 'Yes, with some changes' Max word count = 500]

Please provide suggested changes, including your reasoning or evidence

Recommendation 5 – Quantitation of glycated haemoglobin (a test for diabetes)

Do you agree with Recommendation 5 which proposes to make it clear in the item descriptor that 66551 is restricted under rule 25 to a maximum of four tests per year 66554 to a maximum of six tests per year?

Refer to [Section 5.2.2](#) and the [Summary for consumers](#).

- Yes
- No
- Yes, with some changes
- Don't know / Prefer not to say

[If 'No' or 'Yes, with some changes' Max word count = 500]

Please provide suggested changes, including your reasoning or evidence

Recommendation 6 - Quantitation of glycated haemoglobin (a test for diabetes)

Do you agree with Recommendation 6 which proposes to increase the maximum number of tests for item 66841 to two per year and also provide clearer guidance on medical situations in which the test should be used?

Refer to [Section 5.2.3](#) and the [Summary for consumers](#).

- Yes
- No
- Yes, with some changes
- Don't know / Prefer not to say

[If 'No' or 'Yes, with some changes' Max word count = 500]

Please provide suggested changes, including your reasoning or evidence

Recommendation 7 - Quantitation of fructosamine (glycated albumin)

Do you agree with Recommendation 7 which proposes to provide clearer guidance on when the test for item 66557 is appropriate to use?

Refer to [Section 5.2.4](#) and the [Summary for consumers](#).

- Yes
- No
- Yes, with some changes
- Don't know / Prefer not to say

[If 'No' or 'Yes, with some changes' Max word count = 500]

Please provide suggested changes, including your reasoning or evidence

Recommendation 8 – Microalbumin (a test to detect kidney problems)

Do you agree with Recommendation 8 which proposes to change the title of the test for item 66560 to 'albumin:creatinine ratio' and provide clearer guidance on the specific medical situations in which the test is appropriate and the number of times it should be performed?

Refer to [Section 5.2.5](#) and the [Summary for consumers](#).

- Yes
- No
- Yes, with some changes
- Don't know / Prefer not to say

[If 'No' or 'Yes, with some changes' Max word count = 500]

Please provide suggested changes, including your reasoning or evidence

Recommendation 9 – Quantitation of hormones and hormone-binding proteins

Do you agree with Recommendation 9 which proposes no changes be made to items 66695-66698, 66701, 66704 and 66707 in regards to the quantitation of hormones and hormone-binding proteins?

Refer to [Section 5.3](#) and the [Summary for consumers](#).

- Yes
- No
- Yes, with some changes
- Don't know / Prefer not to say

[If 'No' or 'Yes, with some changes' Max word count = 500]

Please provide suggested changes, including your reasoning or evidence

Recommendation 10 – Thyroid antibodies to tissue antigens

Do you agree with Recommendation 10 which proposes no changes be made to items 71165-71170?

Refer to [Section 5.4](#) and the [Summary for consumers](#).

- Yes
- No
- Yes, with some changes
- Don't know / Prefer not to say

[If 'No' or 'Yes, with some changes' Max word count = 500]

Please provide suggested changes, including your reasoning or evidence

Recommendation 11 – Quantitation of products of collagen breakdown formation
Do you agree with Recommendation 11 which proposes no changes be made to items 66773 and 66776?

Refer to [Section 5.5](#) and the [Summary for consumers](#).

- Yes
- No
- Yes, with some changes
- Don't know / Prefer not to say

[If 'No' or 'Yes, with some changes' Max word count = 500]

Please provide suggested changes, including your reasoning or evidence

Recommendation 12 – Adrenaline and other tests
Do you agree with Recommendation 12 which proposes no changes be made to items 66779 and 66780?

Refer to [Section 5.6](#) and the [Summary for consumers](#).

- Yes
- No
- Yes, with some changes
- Don't know / Prefer not to say

[If 'No' or 'Yes, with some changes' Max word count = 500]

Please provide suggested changes, including your reasoning or evidence

Recommendation 13 – 1, 25-dihydroxivitamin D quantification
Do you agree with Recommendation 13 which proposes no changes be made to items 66835, 66836 and 66837 as they've recently been reviewed and updated?

Refer to [Section 5.7](#) and the [Summary for consumers](#).

- Yes
- No
- Yes, with some changes
- Don't know / Prefer not to say

[If 'No' or 'Yes, with some changes' Max word count = 500]

Please provide suggested changes, including your reasoning or evidence

Recommendation 14 – Hormones and other tests

Do you agree with Recommendation 14 which proposes no changes be made to item 66686?

Refer to [Section 5.8](#) and the [Summary for consumers](#).

- Yes
- No
- Yes, with some changes
- Don't know / Prefer not to say

[If 'No' or 'Yes, with some changes' Max word count = 500]

Please provide suggested changes, including your reasoning or evidence

Recommendation 15 – Quantification in saliva of cortisol

Do you agree with Recommendation 15 which proposes no changes be made to items 66711-66712 and 66714-66715?

Refer to [Section 5.9](#) and the [Summary for consumers](#).

- Yes
- No
- Yes, with some changes
- Don't know / Prefer not to say

[If 'No' or 'Yes, with some changes' Max word count = 500]

Please provide suggested changes, including your reasoning or evidence

Recommendation 16 - Obsolete items

Do you agree with Recommendation 16 which proposes to remove item 66539 from the MBS and instead consider funding two new items for the genetic testing of patients with hereditary high cholesterol and markedly high cholesterol?

Refer to [Section 5.10](#) and the [Summary for consumers](#).

- Yes
- No
- Yes, with some changes
- Don't know / Prefer not to say

[If 'No' or 'Yes, with some changes' Max word count = 500]

Please provide suggested changes, including your reasoning or evidence

If you wish to upload a submission or further evidence to support your responses please upload your file(s) below. Maximum file size is 2MB and files need to be .doc, .docx, .pdf, .xls, .xlsx or .txt. A maximum of 10 files can be uploaded.

Feedback questions

Below are some statements about the Pathology Clinical Committee - Endocrine Tests draft report. For each statement, please indicate whether you agree or disagree.*

	Strongly disagree	Disagree	Neither agree nor disagree	Agree	Strongly Agree	Don't know / Prefer not to say
The Clinical Committee report was easy to understand	()	()	()	()	()	()
There was enough information provided in the Clinical Committee report to support the recommendations	()	()	()	()	()	()
There was enough information provided in the Clinical Committee report for me to understand the recommendations	()	()	()	()	()	()
The Summary for consumers included in the Clinical Committee report was easy to understand	()	()	()	()	()	()

Please provide any further comments or suggestions about the recommendations included in the Pathology Clinical Committee - Endocrine Tests draft report in the space below.

[Max word count = 200]

Please provide any further comments or suggestions in relation to consumer content within the draft report.

[Max word count = 200]

About you

Any personal information provided will be held in compliance with the Australian Privacy Principles (APP) contained in the Privacy Act 1998 and the Privacy (Market and Social Research) Code 2014.

**Are you responding to this consultation as an individual or as a member of an organisation?
If you work within a peak body or health care organisation, please indicate whether you will be primarily answering from an individual or organisational perspective.***

I am responding to this consultation as an INDIVIDUAL

I am responding on behalf of an ORGANISATION

[If 'responding as a member of an organisation']

Please provide the name of the organisation you are responding on behalf of.*

[If 'responding as a member of an organisation']

What type of organisation are you responding on behalf of?

Please just give your best guess if you are unsure.*

Allied health

Peak Body or advocacy organisation

Consumer organisation

General Practice

Medical Specialist Practice

Medical corporation

Other Industry

Public hospital

Private hospital

Indigenous health service

State government

Nursing college

Primary Health Network

Private health insurer

Don't know/ not sure

Other professional - please specify: _____

Other government - please specify: _____

Other non-government - please specify: _____

[If 'responding as a member of an organisation']

In which jurisdictions does your organisation operate?

Please select all those that apply*

- ACT
- New South Wales
- Northern Territory
- Queensland
- South Australia
- Tasmania
- Victoria
- Western Australia
- All Australian States and Territories
- I'd prefer not to say

[If 'responding as an individual']

Are you responding to this consultation primarily as a consumer or health professional?*

- I am responding to this consultation primarily as a CONSUMER
- I am responding to this consultation primarily as a HEALTH PROFESSIONAL
- Don't know / not sure
- Other - please specify: _____

[If 'responding as a health professional']

Have you ever provided services related to Pathology - Endocrine testing?*

- Yes
- No
- Prefer not to say

[If 'responding as a health professional']

Are you a...?*

- Allied Health Professional
- Medical Specialist
- General Practitioner
- Nurse
- Surgeon
- Health worker
- I'd prefer not to say
- Other - please specify: _____

[If 'responding as a consumer']

Have you ever received or accessed services related to Pathology - Endocrine testing?*

- Yes
- No
- Prefer not to say

[If 'responding as an individual']

What is your postcode?*

[If 'responding as an individual']

Do you identify as Aboriginal and/or Torres Strait Islander?*

- Yes, Aboriginal
 - Yes, Torres Strait Islander
 - Yes, Aboriginal and Torres Strait Islander
 - No
 - I'd prefer not to say
-

Privacy consent

The questions below apply to the responses you have provided to the online survey only. Any documentation uploaded, including written feedback will be provided in full to the MBS Review Taskforce and Clinical Committees via the Department of Health.

The MBS Review Taskforce would like to access each full response made to this consultation to inform the recommendations for the final version of the report.

Do you consent to your, or your organisation's response to this survey being provided to the MBS Review Taskforce and Clinical Committee via the Department of Health? *

[If 'responding as an individual'] () Yes, I consent to my response (including the demographic details provided in the previous section) being provided to the MBS Review Taskforce and Clinical Committee

[If 'responding as a member of an organisation'] () Yes, I consent to my organisation's response (including demographic details) being provided to the MBS Review Taskforce and Clinical Committee

[If 'responding as an individual'] () Yes, I consent to my response being provided to the MBS Review Taskforce and Clinical Committee (excluding demographic details)

[If 'responding as a member of an organisation'] () Yes, I consent to my organisation's response being provided to the MBS Review Taskforce and Clinical Committee (excluding demographic details)

[If 'responding as an individual'] () No, I only consent to my response being used for Urbis research purposes and reported to the MBS Review Taskforce and Clinical Committee in aggregate form. (Your response will be only be used by Urbis for research purposes. Aggregated responses will be reported to the Taskforce, along with some non-identifiable example comments.)

[If 'responding as a member of an organisation'] () No, I only consent to my organisation's response being used for Urbis research purposes and reported to the MBS Review Taskforce and Clinical Committee in aggregate form. (Your organisation's response will be only be used by Urbis for research purposes. Aggregated responses will be reported to the Taskforce, along with some non-identifiable example comments.)

[If 'responding as a member of an organisation' and 'providing consent to response being provided to Taskforce']

Please provide your name, organisation details and email address.*

Organisation: _____

Role: _____

Email address: _____

[If 'responding as an individual' and 'providing consent to response being provided to Taskforce']

Please provide your name and email address*

Name: _____

Email address: _____

Privacy consent cont

The MBS Review Taskforce would like to publish a sample of comments made to this consultation.

Do you consent to the comments you made as part of this survey being published by the MBS Review Taskforce? *

[If 'responding as a member of an organisation'] () Yes, I consent to my comments being published and attributed to my organisation

() Yes, I consent to my comments being published but not attributed to me or my organisation

() No, I do not consent to my comments being published

Review your response

Do you want to review your response?

() Yes

() No, I would like to submit my response now

Submit your response

Thank you for providing feedback on the Pathology Clinical Committee - Endocrine Tests report.

Once you click submit your responses will be submitted and you will not be able to view or amend them.

For further information on the Medicare Benefits Schedule Review and the Taskforce please visit the [Health.gov.au website](http://Health.gov.au)

For further information or to report any technical issues with this survey please contact Urbis on mbsreview@urbis.com.au
